Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pociredir - Fulcrum Therapeutics

Next Previous
Drug Profile

Pociredir - Fulcrum Therapeutics

Alternative Names: FTX HbF; FTX-6058

Latest Information Update: 12 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fulcrum Therapeutics
  • Class Antianaemics; Heterocyclic compounds with 4 or more rings; Pyridines; Small molecules
  • Mechanism of Action EED protein inhibitors; Fetal haemoglobin expression stimulants; Polycomb repressive complex 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Sickle cell anaemia
  • No development reported Beta-thalassaemia

Most Recent Events

  • 02 May 2025 Phase I development in Sickle cell anaemia is ongoing South Africa
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in South Africa (PO, Capsule)
  • 13 Nov 2024 Fulcrum Therapeutics plans a phase I trial (In volunteers)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top